Diabetes Obesity and Metabolism,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 22, 2025
Abstract
Aims
Glucagon‐like
peptide
1
receptor
agonists
(GLP1RA),
used
to
treat
type
2
diabetes
and
obesity,
have
been
associated
with
off‐target
behavioural
effects.
We
systematically
assessed
genetic
variation
in
the
GLP1R
locus
for
impact
on
mental
ill‐health
(MIH)
cardiometabolic
phenotypes
across
diverse
populations
within
UK
Biobank.
Materials
Methods
All
variants
minor
allele
frequency
>1%
were
investigated
associations
MIH
phenotypes.
Linear
or
Logistic
regression
analyses
(adjusted
age,
sex,
population
structure
genotyping
chip)
conducted
separately
unrelated
individuals
of
self‐reported
white
British
(
N
=
408
774),
European
50
314),
South
Asian
7667),
multiple‐ancestry
groups
10
437)
African‐Caribbean
7641)
subsets.
ancestries
subsequently
combined
an
inverse
variance‐weighted
fixed
effects
meta‐analysis.
Bonferroni
correction
multiple
testing
was
applied
(for
number
independent
variants).
Results
Associations
identified
between
body
mass
index
(BMI),
blood
pressure
all
ancestries.
except
had
significant
(mood
instability:
rs111265626‐G,
odds
ratio
[OR]
0.851
[confidence
interval,
CI
0.79–0.92],
risk‐taking
behaviour:
rs75408972‐T,
OR
1.05
[CI
1.03–1.08]
chronic
pain:
rs9296280‐C,
0.645
0.54–0.78]).
The
trans‐ancestry
meta‐analysis
showed
mainly
consistent
effect
sizes
directions
metabolic
traits,
but
discordant
associations.
Only
signals
pain,
stroke
BMI
influenced
expression
.
Conclusions
ancestries,
are
more
varied.
Any
observed
changes
GLP1RA
likely
not
acting
directly
through
Medicine,
Год журнала:
2024,
Номер
103(18), С. e37928 - e37928
Опубликована: Май 3, 2024
Background:
Glucagon-like
peptide-1
receptor
agonists
(GLP-1RAs)
like
liraglutide
are
primarily
used
for
managing
blood
sugar
levels
in
type
2
diabetes
and
aiding
weight
loss.
Typically,
their
adverse
effects
gastrointestinal,
with
limited
exploration
into
impact
on
mental
health.
Case
presentation:
This
report
examines
a
39-year-old
male
who
developed
depressive
symptoms
after
starting
glycemic
control
reduction.
Symptoms
included
poor
mood,
irritability,
decreased
interest
energy,
progressing
to
sadness,
low
self-esteem,
physical
discomfort.
A
clinical
diagnosis
of
episode
was
made,
coinciding
the
initiation
liraglutide.
Intervention
outcome:
The
patient
significantly
improved
within
week
discontinuing
antidepressant
therapy.
suggests
possible
link
between
depression,
despite
considering
other
factors
diabetes-related
stress.
Discussion:
explores
potential
mechanisms,
such
as
GLP-1RA
glucose
fluctuations
dopamine
modulation,
which
might
contribute
symptoms.
influence
brain
reward
system
reduction
cravings
addictive
substances
use
is
also
discussed
factor
mood
regulation.
Conclusion:
case
highlights
necessity
being
vigilant
about
psychiatric
side
effects,
particularly
associated
GLP-1RAs.
rarity
reports
calls
more
research
investigate
understand
these
implications
further.
Journal of Addiction Medicine,
Год журнала:
2024,
Номер
18(5), С. 488 - 498
Опубликована: Авг. 1, 2024
Abstract
Substance
use
disorder
(SUD)
continues
to
be
a
leading
cause
of
morbidity
and
mortality
with
limited
treatments.
There
is
interest
in
expanding
the
GLP-1
agonists
treating
SUD.
However,
evidence
for
safety
efficacy
humans
limited.
This
review
aims
bridge
existing
knowledge
gap
by
establishing
baseline
literature
this
area
inform
future
trials
clinical
practice.
Our
inclusion
criteria
were
English
peer-reviewed
manuscripts
reporting
on
GLP-1,
GIP,
and/or
glucagon
receptor
treatment
SUDs,
excluding
case
studies.
The
search
was
performed
accordance
PRISMA
guidelines.
Five
studies
included
examining
medication
tobacco
disorder,
alcohol
cocaine
disorder.
No
regarding
substance
withdrawal
syndrome
identified.
varied
widely
terms
patient
selection,
dose/formulation
agonists,
follow-up.
results
scoping
are
mixed,
3
demonstrating
positive
2
finding
no
SUD
outcomes.
It
premature
prescribe
off-label
patients.
Further
research
needed
determine
Diabetes Obesity and Metabolism,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 22, 2025
Abstract
Aims
Glucagon‐like
peptide
1
receptor
agonists
(GLP1RA),
used
to
treat
type
2
diabetes
and
obesity,
have
been
associated
with
off‐target
behavioural
effects.
We
systematically
assessed
genetic
variation
in
the
GLP1R
locus
for
impact
on
mental
ill‐health
(MIH)
cardiometabolic
phenotypes
across
diverse
populations
within
UK
Biobank.
Materials
Methods
All
variants
minor
allele
frequency
>1%
were
investigated
associations
MIH
phenotypes.
Linear
or
Logistic
regression
analyses
(adjusted
age,
sex,
population
structure
genotyping
chip)
conducted
separately
unrelated
individuals
of
self‐reported
white
British
(
N
=
408
774),
European
50
314),
South
Asian
7667),
multiple‐ancestry
groups
10
437)
African‐Caribbean
7641)
subsets.
ancestries
subsequently
combined
an
inverse
variance‐weighted
fixed
effects
meta‐analysis.
Bonferroni
correction
multiple
testing
was
applied
(for
number
independent
variants).
Results
Associations
identified
between
body
mass
index
(BMI),
blood
pressure
all
ancestries.
except
had
significant
(mood
instability:
rs111265626‐G,
odds
ratio
[OR]
0.851
[confidence
interval,
CI
0.79–0.92],
risk‐taking
behaviour:
rs75408972‐T,
OR
1.05
[CI
1.03–1.08]
chronic
pain:
rs9296280‐C,
0.645
0.54–0.78]).
The
trans‐ancestry
meta‐analysis
showed
mainly
consistent
effect
sizes
directions
metabolic
traits,
but
discordant
associations.
Only
signals
pain,
stroke
BMI
influenced
expression
.
Conclusions
ancestries,
are
more
varied.
Any
observed
changes
GLP1RA
likely
not
acting
directly
through
